Life AI Net
홈
아카이브
계산기
디렉토리
뉴스레터
Hot
로그인
한국어
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
홈
아카이브
계산기
디렉토리
뉴스레터
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
로그인
홈
아카이브
계산기
디렉토리
More
실시간
FierceBiotech
Foundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target
FierceBiotech
In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
FierceBiotech
Ray Therapeutics shines a light on $125M round targeting genetic eye therapy
FierceBiotech
Tortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from Asia
FierceBiotech
Pfizer's strategy head Andrew Baum to step down following brief tenure: reports
Lonza News
Simulations Plus (SLP) Partners with FDA and Lonza for Drug Perf - GuruFocus
Lonza News
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks fo - PharmiWeb.com
Lonza News
Simulations Plus partners with Lonza and FDA on drug formulation research - Investing.com
BioWorld
Japanese researchers report new μ-opioid receptor antagonists
BioWorld
Incyte discloses new TYK2 and/or JAK1 inhibitors
BioWorld
Insilico Medicine divulges new NLRP3 inflammasome inhibitors
BioWorld
Neolaia synthesizes new CD38 inhibitors
FierceBiotech
Foundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target
FierceBiotech
In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
FierceBiotech
Ray Therapeutics shines a light on $125M round targeting genetic eye therapy
FierceBiotech
Tortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from Asia
FierceBiotech
Pfizer's strategy head Andrew Baum to step down following brief tenure: reports
Lonza News
Simulations Plus (SLP) Partners with FDA and Lonza for Drug Perf - GuruFocus
Lonza News
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks fo - PharmiWeb.com
Lonza News
Simulations Plus partners with Lonza and FDA on drug formulation research - Investing.com
BioWorld
Japanese researchers report new μ-opioid receptor antagonists
BioWorld
Incyte discloses new TYK2 and/or JAK1 inhibitors
BioWorld
Insilico Medicine divulges new NLRP3 inflammasome inhibitors
BioWorld
Neolaia synthesizes new CD38 inhibitors
아카이브
검색
검색
최신
오래된 순
지우기
@BioWorld
전체
1057
출처
BioWorld
검색어
--
BioWorld
2026년 3월 25일
Early FDA wins: Corcept’s Lifyorli, Denali’s Avlayah
BioWorld
2026년 3월 25일
Chinese researchers synthesize NO production inhibitors
BioWorld
2026년 3월 25일
Kyungpook National University identifies OTU1-targeting peptides
BioWorld
2026년 3월 25일
TYK Medicines discloses new CDK4 inhibitors
BioWorld
2026년 3월 25일
Yuhan presents new GLP-1R agonists
BioWorld
2026년 3월 24일
Australia’s R&D reset puts biotech translation in focus
BioWorld
2026년 3월 24일
Simcere’s PD-L1/IL-15 bispecific sees early edge in bladder cancer
BioWorld
2026년 3월 24일
How to grow a startup in the AI era: MedTech Spotlight Korea 2026
BioWorld
2026년 3월 24일
Imbiologics crosses $1B market cap with Kosdaq debut
BioWorld
2026년 3월 24일
Excalipoint closes $68.7M seed round for cancer T-cell engagers
BioWorld
2026년 3월 24일
Nanyang researchers discover molephantinin derivatives
BioWorld
2026년 3월 24일
Council of Scientific and Industrial Research identifies new PARP-1 inhibitors
BioWorld
2026년 3월 24일
New coumarin compounds reported in Simcere patent
BioWorld
2026년 3월 24일
Qilu Pharma describes new VAV1 degradation inducers
BioWorld
2026년 3월 23일
G2Gbio secures license deal, ₩20B investment from Samsung Epis
BioWorld
2026년 3월 23일
US Supreme Court says no to Takeda class action challenge
BioWorld
2026년 3월 23일
Appointments and advancements for March 23, 2026
BioWorld
2026년 3월 23일
Financings for March 23, 2026
이전
11 / 59
다음